Sector News

Axovant poaches Allergan CMO to lead R&D recovery

May 29, 2018
Life sciences

Axovant has put Gavin Corcoran in charge of its R&D recovery. Corcoran is stepping down as CMO of Allergan to take up the position, which will see him try to guide Axovant back from the implosion of its Alzheimer’s R&D strategy.

The R&D strategy went off the rails last year when intepirdine failed a phase 3 trial. That led Axovant to dump the 5-HT6 inhibitor at the start of 2018 and later part company with multiple directors and senior executives, including CEO David Hung, M.D. The reorganization put Pavan Cheruvu, M.D., in charge of slimming down the business and refocusing it on different assets. Now, Cheruvu has brought Corcoran on board to support the effort.

Corcoran has spent the past few years working as CMO of Allergan. Like Brent Saunders, Corcoran used the series of mergers involving Forest Laboratories, Actavis and Allergan to secure leadership positions at progressively bigger firms.

In taking up the position of EVP of R&D at Axovant, Corcoran has reversed the process, landing at a smaller but nonetheless closely-scrutinized company. Corcoran arrives at a time when Axovant is still figuring out which assets to focus on in its postintepirdine era. That gives the new arrival a chance to influence the list of drugs that will dominate his attention at Axovant.

“I look forward to working closely with Pavan and the senior management team to bring new investigational medicines into the portfolio as we build upon Axovant’s capabilities in research and development,” Corcoran said in a statement.

Axovant unveiled Corcoran in a statement that also revealed Michael Hayden, Ph.D., has agreed to head up its new scientific advisory board. Hayden was a casualty of the upheaval at Teva, where he served as CSO until recently installed CEO Kare Schultz decided to remove him and two other heads of key divisions.

Corcoran and Hayden join a company that has just come through a reorganization that saw it shed more than 40% of its employees. The new-look company will lean more heavily on parent company Roivant for support.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend